Relevant bibliographies by topics / Androstenedione

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Androstenedione'

Author: Grafiati
Published: 4 June 2021
Last updated: 12 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Androstenedione.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Androstenedione"

1

Ziegenfuss, Tim N., John M. Berardi, Lonnie M. Lowery, and Jose Antonio. "Effects of Prohormone Supplementation in Humans: A Review." Canadian Journal of Applied Physiology 27, no. 6 (December 1, 2002): 628–45. http://dx.doi.org/10.1139/h02-037.

Full text
Abstract:
Despite a relative dearth of information on their effects, supplementation with prohormones has become a popular practice. Unlike synthetic anabolic-androgenic steroids, many of these over-the-counter androgens are produced endogenously by adrenal, gonadal and peripheral steroidogenic pathways as part of the normal sexual and reproductive hormonal milieu. It has been contended that peripheral enzymatic conversion of these prohormones to testosterone or nortestosterone (via ingestion of androstenedione/androstenediol or 19-nor-androstenedione/androstenediol, respectively) might lead to anabolic and/or ergogenic effects. Existing data suggest that acute oral ingestion of >= 200 mg androstenedione or androstenediol modestly and transiently increases serum testosterone concentrations in men; however, this is accompanied by greater increases in circulating estrogen(s). At doses < 300 mg/d, oral supplementation for as long as 12-weeks with androstenedione or androstenediol has no effect on body composition or physical performance and decreases high-density lipoprotein cholesterol. Similarly, oral supplementation with norandrostenedione and norandrostenediol for up to eight weeks has no effect on body composition or physical performance. In light of these data, new products have been developed that use alternative modes of prohormone administration (sublingual/transbuccal and cyclodextrin-complexation). Future studies should critically examine the effects of these approaches. However, within the framework of the research reviewed, over-the-counter oral prohormone supplementation is ineffective at increasing muscle mass or athletic performance. As a result of the potential health concerns that have been raised, the risk to benefit ratio of using these substances orally seems unfavorable. Keywords: androstenediol, androstenedione, norandrostenedione, norandrostenediol, ergogenic aid
APA, Harvard, Vancouver, ISO, and other styles
2

Gwartney, Daniel L., and Jeffrey R. Stout. "Androstenedione." Strength and Conditioning Journal 21, no. 1 (February 1999): 65. http://dx.doi.org/10.1519/00126548-199902000-00016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dlugovitzky, Diana G., María Sol Fontela, Diego J. Martinel Lamas, Ricardo A. Valdez, and Marta C. Romano. "Mycobacterium smegmatis synthesizes in vitro androgens and estrogens from different steroid precursors." Canadian Journal of Microbiology 61, no. 7 (July 2015): 451–55. http://dx.doi.org/10.1139/cjm-2015-0025.

Full text
Abstract:
Fast-growing mycobacteria such as Mycobacterium sp. and Mycobacterium smegmatis degrade natural sterols. They are a model to study tuberculosis. Interestingly, M. smegmatis has been found in river effluents derived from paper production, and therefore, it would be important to gain further insight into its capacity to synthesize steroids that are potential endocrine disruptors affecting the development and reproduction of fishes. To our knowledge, the capacity of M. smegmatis to synthesize estrogens and even testosterone has not been previously reported. Therefore, the objective of this study was to investigate the capacity of M. smegmatis to synthesize in vitro testosterone and estrogens from tritiated precursors and to investigate the metabolic pathways involved. Results obtained by thin-layer chromatography showed that 3H-progesterone was transformed to 17OH-progesterone, androstenedione, testosterone, estrone, and estradiol after 6, 12, or 24 h of incubation. 3H-androstenedione was transformed into testosterone and estrogens, mainly estrone, and 3H-testosterone was transformed to estrone and androstenedione. Incubation with 3H-dehydroepiandrosterone rendered androstenediol, testosterone, and estrogens. This ability to transform less potent sex steroids like androstenedione and estrone into other more active steroids like testosterone and estradiol or vice versa suggests that M. smegmatis can influence the amount of self-synthesized strong androgens and estrogens and can transform those found in the environment.
APA, Harvard, Vancouver, ISO, and other styles
4

Broeder, Craig E. "Oral Andro-Related Prohormone Supplementation: Do the Potential Risks Outweigh the Benefits?" Canadian Journal of Applied Physiology 28, no. 1 (February 1, 2003): 102–16. http://dx.doi.org/10.1139/h03-009.

Full text
Abstract:
Androstenedione, 4-androstenediol, 5-androstenediol, 19-norandrostenediol and 19-norandrostenedione are commonly referred to as "Andro" prohormones. Over the last few years, supplementation using these prohormones has been aggressively marketed to the general public. Supplement manufacturers often claim that Andro use improves serum testosterone concentrations, increases muscular strength and muscle mass, helps to reduce body fatness, enhances mood, and improves sexual performance. However, to date, most studies contradict these claims. In contrast, several studies using oral Andro related prohormones show that Andro use can abnormally elevate estrogen related hormones as well as alterations in hormonal markers (i.e., abnormal elevations in serum estrogen) thought to increase a person's risk for developing prostate or pancreatic cancers. In addition, most studies also indicate that significant declines in high-density lipoproteins occur leading to an increased cardiovascular disease risk. Thus, to date, the current research base suggests that Andro prohormone use does not support manufacturer claims. But it does suggest there should be strong concerns regarding long-term oral Andro prohormone use, especially regarding its effects on blood lipids and estrogen hormone profiles. Key words: resistance exercise, androstenedione, androstenediol, anti-aging
APA, Harvard, Vancouver, ISO, and other styles
5

Brown, Gregory A., Emily R. Martini, B. Scott Roberts, Matthew D. Vukovich, and Douglas S. King. "Acute hormonal response to sublingual androstenediol intake in young men." Journal of Applied Physiology 92, no. 1 (January 1, 2002): 142–46. http://dx.doi.org/10.1152/jappl.2002.92.1.142.

Full text
Abstract:
The effectiveness of orally ingested androstenediol in raising serum testosterone concentrations may be limited because of hepatic breakdown of the ingested androgens. Because androstenediol administered sublingually with cyclodextrin bypasses first-pass hepatic catabolism, we evaluated the acute hormonal response to sublingual cyclodextrin androstenediol supplement in young men. Eight men (22.9 ± 1.2 yr) experienced in strength training consumed either 20 mg androstenediol in a sublingual cyclodextrin tablet (Sl Diol) or placebo (Pl) separated by at least 1 wk in a randomized, double-blind, crossover manner. Blood samples were collected before supplementation and at 30-min intervals for 3 h after supplementation. Serum hormone concentrations did not change with Pl. Serum androstenedione concentrations were increased ( P < 0.05) above baseline (11.2 ± 1.1 nmol/l) with Sl Diol from 60 to 180 min after intake and reached a peak concentration of 25.2 ± 2.9 nmol/l at 120 min. Serum free testosterone concentrations were increased from 86.2 ± 9.1 pmol/l with Sl Diol from 30 to 180 min and reached a peak concentration of 175.4 ± 12.2 pmol/l at 60 min. Serum total testosterone concentrations increased above basal (25.6 ± 2.3 nmol/l) from 30 to 180 min with Sl Diol and reached a peak concentration of 47.9 + 2.9 nmol/l at 60 min. Serum estradiol concentrations were elevated ( P < 0.05) above baseline (0.08 ± 0.01 nmol/l) from 30 to 180 min with Sl Diol and reached 0.14 ± 0.02 nmol/l at 180 min. These data indicate that sublingual cyclodextrin androstenediol intake increases serum androstenedione, free testosterone, total testosterone, and estradiol concentrations.
APA, Harvard, Vancouver, ISO, and other styles
6

Rasmussen, Blake B., Elena Volpi, Dennis C. Gore, and Robert R. Wolfe. "Androstenedione Does Not Stimulate Muscle Protein Anabolism in Young Healthy Men1." Journal of Clinical Endocrinology & Metabolism 85, no. 1 (January 1, 2000): 55–59. http://dx.doi.org/10.1210/jcem.85.1.6322.

Full text
Abstract:
Androstenedione is the immediate precursor of testosterone. Androstenedione intake has been speculated to increase plasma testosterone levels and muscle anabolism. Thus, androstenedione supplements have become widely popular in the sport community to improve performance. This study was designed to determine whether 5 days of oral androstenedione (100 mg/day) supplementation increases skeletal muscle anabolism. Six healthy young men were studied before the treatment period and after 5 days of oral androstenedione supplementation. Muscle protein turnover parameters were compared to those of a control group studied twice as well and receiving no treatment. We measured muscle protein kinetics using a three-compartment model involving infusion of l-[ring-2H5]phenylalanine, blood sampling from femoral artery and vein, and muscle biopsies. Plasma testosterone, androstenedione, LH, and estradiol concentrations were determined by RIA. After ingestion of oral androstenedione, plasma testosterone and LH concentrations did not change from basal, whereas plasma androstenedione and estradiol concentrations were significantly increased (P &lt; 0.05). Compared to a control group, androstenedione did not affect muscle protein synthesis and breakdown, or phenylalanine net balance across the leg. We conclude that oral androstenedione does not increase plasma testosterone concentrations and has no anabolic effect on muscle protein metabolism in young eugonadal men.
APA, Harvard, Vancouver, ISO, and other styles
7

Lea, CK, V. Moxham, MJ Reed, and AM Flanagan. "Androstenedione treatment reduces loss of cancellous bone volume in ovariectomised rats in a dose-responsive manner and the effect is not mediated by oestrogen." Journal of Endocrinology 156, no. 2 (February 1, 1998): 331–39. http://dx.doi.org/10.1677/joe.0.1560331.

Full text
Abstract:
We have tested the hypothesis that androstenedione (administered as 21-day, slow-release pellets) is converted to active sex steroids and reduces bone turnover in the ovariectomised rat model. We found that ovariectomy resulted in a minor but significant reduction in plasma concentrations of androstenedione and testosterone and a more significant reduction in oestrone (E1) and oestradiol (E2). This was associated with the expected substantial loss of metaphyseal cancellous bone volume. Androstenedione (1.5-100 mg) pellets increased the plasma concentrations of androstenedione and testosterone above those in the ovariectomised (ovx) rats in a dose-responsive manner, whereas E2 plasma concentrations were increased to a minor but significant degree above those in the ovx animals. Androstenedione reduced loss of cancellous bone volume in a dose-dependent fashion by reducing bone turnover. The 1.5, 5 and 100 mg androstenedione-induced effect on bone turnover was not abrogated by simultaneous treatment with Arimidex, an aromatase inhibitor. This implies that the skeletal-protective effect of androstenedione was not oestrogen-mediated.
APA, Harvard, Vancouver, ISO, and other styles
8

Doggui, Radhouene. "Immunoanalytical profile of androstenedione." Annales de biologie clinique 74, no. 4 (July 2016): 495–502. http://dx.doi.org/10.1684/abc.2016.1171.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

&NA;. "Beware of androstenedione contamination." Inpharma Weekly &NA;, no. 1266 (December 2000): 19. http://dx.doi.org/10.2165/00128413-200012660-00049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Thomson, S., A. M. Wallace, and B. Cook. "A 125I-radioimmunoassay for measuring androstenedione in serum and in blood-spot samples from neonates." Clinical Chemistry 35, no. 8 (August 1, 1989): 1706–12. http://dx.doi.org/10.1093/clinchem/35.8.1706.

Full text
Abstract:
Abstract We developed a radioimmunoassay with a gamma-emitting radioligand to measure androstenedione in human serum and in dried blood-spot samples from newborns. Antisera were raised in rabbits against androstenedione linked to bovine serum albumin at positions 3, 6, or 11 on the steroid nucleus. Radioligands were prepared by linking [125I]iodohistamine at positions 3, 6, or 11. Linkages were through either carboxymethyloxime or hemisuccinate bridges. All label and antibody combinations were examined, and the most sensitive and specific combination (antiserum raised against androstenedione-3-carboxymethyloxime-bovine serum albumin with an androstenedione-carboxymethyloxime-[125I]iodohistamine label) was selected for full evaluation. We report the performance of these selected reagents in an immunoassay for androstenedione in both serum and dried blood-spot samples from neonates. We measured concentrations of androstenedione in serum under normal and pathological conditions such as congenital adrenal hyperplasia and polycystic ovarian disease. Diurnal variation in normal men was observed. Androstenedione was measured in blood spots from neonates born at term or prematurely, with respiratory distress syndrome, or with congenital adrenal hyperplasia.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Androstenedione"

1

Biggs, Douglas Neil. "Effects of androstenedione supplementation on testosterone levels in older men." Virtual Press, 2002. http://liblink.bsu.edu/uhtbin/catkey/1233193.

Full text
Abstract:
The purpose of this study was to examine the effects of androstenedione supplementation on testosterone levels in older men. Healthy men (n = 11) between the ages of58 and 69 were divided into two groups: 6 taking 300 mg of androstenedione (mean ± SE, 62.33 ± 2.57) supplement and 5 taking the 300 mg cellulose placebo (mean ± SE, 60.2 ± 1.02) for a period of seven days. Subjects in both groups had been participating in the Ball State University Adult Fitness Program (BSUAFP) for at least one year, incorporating both aerobic and resistance training into their workouts. Testing measures involved the subjects performing two exercises (leg extension and leg curl) while having blood drawn prior to, during, and post-exercise for a period of 20 minutes both pre-and post-supplementation. Specific weights for the subjects were determined with a ten-repetition maximum (10-RM) lift on both exercises. It appeared that the subjects in the androstenedione group were stronger with the exercises than the subjects in the placebo group, but with no significance. Testosterone, estradiol, and androstenedione were analyzed via hormone assay pre-and post-supplementation. The analysis of the testosterone revealed a significant difference pre-(mean ± SE, 4.65 ± .51 ng/ml) to post-(mean ± SE, 6.72 ± .58 ng/ml) supplementation for the androstenedione group. Analysis of the androstenedione revealed a significant difference pre-(mean ± SE, 0.88 ± .20) to post-(mean ± SE, 7.46 ± 1.25) supplementation for the androstenedione group. The estradiol assay revealed no significant differences pre-to post-supplementation for either group. The placebo group did not demonstrate any significant differences pre-to post-supplementation for either testosterone or androstenedione. The results of this study concluded that supplementation with 300 mg. of androstenedione for a period of seven days significantly elevated blood testosterone in older men.
School of Physical Education
APA, Harvard, Vancouver, ISO, and other styles
2

Bassindale, Thomas Alexander. "Analytical perspectives and endocrine implications of androstenedione administration to young women." Thesis, King's College London (University of London), 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.409256.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Stevens, Jeffrey Charles 1963. "Selective inactivation of four rat liver microsomal androstenedione hydroxylases by chloramphenicol analogs." Thesis, The University of Arizona, 1988. http://hdl.handle.net/10150/276700.

Full text
Abstract:
The steroid androstenedione has been shown to be a valuable tool for the study of selective inactivation of rat liver cytochrome P-450 isozymes. The validity of this method was investigated using microsomes, purified cytochromes P-450, cytochrome P-450 antibodies, and the mechanism-based inactivator chloramphenicol. Enzyme inactivation and antibody inhibition studies show that microsomes from phenobarbital- and non-phenobarbital-treated rats are needed to accurately monitor the inactivation of the major phenobarbital-inducible P-450 isozyme (PB-B) and of the major constitutive androstenedione 16-alpha hydroxylase (UT-A). Enzyme inactivation studies showed that the antibiotic chloramphenicol caused different rates of NADPH-dependent enzyme inactivation among four androstenedione hydroxylases (16-beta > 6-beta > 16-alpha > 7-alpha). The results with twelve chloramphenicol analogs show that their selectivity as cytochrome P-450 inactivators is dependent upon at least three structural features: (1) the number of halogen atoms, (2) the presence of a para-nitro group on the phenyl ring, and (3) substitutions on the ethyl side chain.
APA, Harvard, Vancouver, ISO, and other styles
4

Williams, Terry L. "Assessment of knowledge regarding three popular dietary supplements : chromium picolinate, creatine, and androstenedione /." View online, 2000. http://repository.eiu.edu/theses/docs/32211130977235.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wills, Troy Matthew. "The osteogenic effects of 12 weeks of oral supplementation of androstenedione in middle-aged men." [Johnson City, Tenn. : East Tennessee State University], 2003. http://etd-submit.etsu.edu/etd/theses/available/etd-1107103-104810/unrestricted/WillsT112503f.pdf.

Full text
Abstract:
Thesis (M.A.)--East Tennessee State University, 2003.
Title from electronic submission form. ETSU ETD database URN: etd-1107103-104810. Includes bibliographical references. Also available via Internet at the UMI web site.
APA, Harvard, Vancouver, ISO, and other styles
6

ZEINOUN, RONY. "Profil hormonal intrafolliculaire au cours des stimulations ovariennes : valeur predictive pour le succes d'une f.i.v." Reims, 1990. http://www.theses.fr/1990REIMM086.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Clark, Douglas Taylor. "An investigation of the metabolism of testosterone, 4 androstenedione, progesterone, corticosterone, cortisol and cholesterol by T. denticola." Thesis, King's College London (University of London), 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.249230.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Viciano, Gonzalo Ignacio. "A theoretical study on the mechanism of the oxidation of substrates by human aromatase enzyme (CYP19A1)." Doctoral thesis, Universitat Jaume I, 2016. http://hdl.handle.net/10803/392148.

Full text
Abstract:
The enzyme Cytochrome P450 aromatase plays an essential role in the biosynthesis of estrogens, and its inhibition is an important target for the development of drugs for the treatment of breast cancer. The main purpose of the present thesis is to improve the understanding of the catalytic mechanism and the biochemistry of this enzyme from the standpoint of theoretical chemistry. The results of this thesis have been divided into three main sections: (1) Study of the reactive species of the enzyme aromatase: Compound I; (2) Study of the hydroxylation of the natural substrate androstenedione, during the first catalytic subcycle of the enzyme aromatase; and (3) Study of the hydroxylation of Exemestane, an esteroidal third generation aromatase inhibitor, currently used in hormone dependent breast cancer therapy.
La enzima citocromo P450 aromatasa juega un papel esencial en la biosíntesis de estrógenos, y su inhibición es un objetivo importante para el desarrollo de medicamentos para el tratamiento del cáncer de mama. El objetivo principal de la esta Tesis ha sido arrojar luz sobre el mecanismo catalítico y sobre la bioquímica de esta enzima, desde el punto de vista de la química teórica. Los resultados que se presentan en esta Tesis se han dividido en tres secciones principales: (1) Estudio de la especie reactiva de la enzima aromatasa: "Compound I"; (2) Estudio de la hidroxilación del substrato natural androstenediona, a lo largo del primer subciclo catalítico de esta enzima; y (3) Estudio de la hidroxilación del Exemestano, un inhibidor esteroideo de tercera generación de la enzima aromatasa, que se utiliza actualmente en el tratamiento del cáncer de mama hormonodependiente.
APA, Harvard, Vancouver, ISO, and other styles
9

Saleh, Layla. "Effets de l'administration in ovo de thyrolibérine, thyroxine, propylthiouracile et androstenedione sur la croissance postnatale du poulet avec quelques aspects biochimiques et histoenzymologiques de la différenciation musculaire." Grenoble 2 : ANRT, 1988. http://catalogue.bnf.fr/ark:/12148/cb37618405b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Murigneux, Christine. "Evolution des concentrations plasmatiques de androstenedione, dht, dha, dha-s, t, corticosterone et cortisol chez les lapins males et femelles de la periode prepubertaire a l'age adulte." Clermont-Ferrand 2, 1986. http://www.theses.fr/1986CLF2S847.

Full text
Abstract:
Chez le lapin male ou femelle entre 40 et 150 jours, une methode par chromatographie liquide sur silice greffee permet de separer les 7 steroides. Au cours de la maturation sexuelle, il se produit d'importantes variations de concentrations plasmatiques d'androgenes dans les 2 sexes (episodes secretoires de quelques dizaines de jours). Il n'y a pas de dimorphisme sexuel pour les taux plasmatiques d'androstenedione, de dha et de son sulfate, on peut donc penser que la secretion en est surrenalienne. Chez les femelles, il existe une correlation entre les concentrations d'androgenes et celles de corticosterone ou de cortisol, ce qui suggere que les androgenes sont d'origine surrenalienne. Quelque soit l'origine des androgenes, le probleme de la signification de l'androgenisation plasmatique se pose, notamment entre 70 et 110 jours. Au cours de la maturation sexuelle, il se produit des modifications de synthese dans la surrenale, car chez le lapin adulte male ou femelle, la corticosterone est le principal steroide secrete, tandis que chez l'animal immature, elle est faible et meme inferieure a la corticolemie. Chez le foetus, les observations sont similaires
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Androstenedione"

1

The smart guide to Andro: The safe and natural testosterone precursor for sex and athletic enhancement. Petaluma, CA: Smart Publications, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Parker, James N., and Philip M. Parker. Androstenedione: A medical dictionary, bibliography, and annotated research guide to internet references. San Diego, CA: ICON Health Publications, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Anabolic steroids and sports, testing, creatine, androstenedione, and other ergogenic aids: Spring 1998-spring 2005: an annotated bibliography. Albany, NY: Whitston Pub., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Super "T": The Complete Guide to Creating an Effective, Safe and Natural Testosterone Enhancement Program for Men and Women. Fireside, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hawken, C. M. Andro Effect: Using Androstenedione to Enhance Testosterone Production (Woodland Health). Woodland Publishing, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Publications, ICON Health. Androstenedione - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References. ICON Health Publications, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Paterson, Ellen R. Anabolic Steroids And Sports, Testing, Creatine, Androstenedione, And Other Ergogenic AIDS: Spring 1998-spring 2005: An Annotated Bibliography. Whitston Publishing Company, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Natural Power Builders: The Pros and Cons. St. Martin's Paperbacks, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Aromatase Inhibition. Parthenon Publishing Group, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

M, Dowsett, ed. Aromatase inhibition: Then, now, and tomorrow. London: Parthenon Pub. Group, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Androstenedione"

1

Josefsen, Kjell D., Anna Nordborg, and Håvard Sletta. "Bioconversion of Phytosterols into Androstenedione by Mycobacterium." In Microbial Steroids, 177–97. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7183-1_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Martínez-Cámara, Sonia, Esther Bahíllo, José-Luis Barredo, and Marta Rodríguez-Sáiz. "Scale-Up of Phytosterols Bioconversion into Androstenedione." In Microbial Steroids, 199–210. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7183-1_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Marques, Marco P. C., and Pedro Fernandes. "β-Sitosterol Bioconversion to Androstenedione in Microtiter Plates." In Microbial Steroids, 167–76. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7183-1_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Thomson, S., A. M. Wallace, and B. Cook. "A ‘Blood Spot’ Androstenedione Radioimmunoassay Able to Detect Congenital Adrenal Hyperplasia." In Studies in Inherited Metabolic Disease, 318–20. Dordrecht: Springer Netherlands, 1989. http://dx.doi.org/10.1007/978-94-009-1069-0_39.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Leder, Benjamin. "Androstenedione." In Encyclopedia of Dietary Supplements, Second Edition, 15–20. CRC Press, 2010. http://dx.doi.org/10.1201/b14669-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Safran, Marc R., James Zachazewski, and David A. Stone. "Androstenedione." In Instructions for Sports Medicine Patients, 73. Elsevier, 2012. http://dx.doi.org/10.1016/b978-1-4160-5650-8.00111-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kaye, Adam M., and Alan Kaye. "Androstenedione." In Essence of Anesthesia Practice, 656. Elsevier, 2011. http://dx.doi.org/10.1016/b978-1-4377-1720-4.00576-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Leder, Benjamin. "Androstenedione." In Encyclopedia of Dietary Supplements, 7–13. CRC Press, 2004. http://dx.doi.org/10.1201/b13959-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Allolio, B., and W. Arlt. "Dehydroepiandrosterone (DHEA) and androstenedione." In Testosterone, 597–622. Cambridge University Press, 2001. http://dx.doi.org/10.1017/cbo9780511545221.020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

"Androstenedione = Benjamin Z. Leder." In Encyclopedia of Dietary Supplements (Online), 27–34. CRC Press, 2004. http://dx.doi.org/10.1201/b13959-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Androstenedione"

1

Bleach, RM, L. Creevey, ADK Hill, S. Madden, LS Young, SR Pennington, and M. McIlroy. "Abstract P4-04-13: Androstenedione initiates rapid non-genomic signalling mediated by cytoplasmic androgen receptor in aromatase inhibitor resistant breast cancer." In Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.sabcs17-p4-04-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bleach, R., L. Creevey, S. Madden, L. Young, S. Pennington, and M. McIlroy. "PO-178 Androstenedione (4AD) activates an androgen receptor (AR) mediated transcriptome and AR interactions associated with cell-cell adhesion in aromatase inhibitor (AI) resistant breast cancer cells." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.699.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ibrahim-zada, Irada, James N. Ingle, Brooke L. Fridley, Aman Buzdar, Mark E. Robson, Michiaki Kubo, Anthony Batzler, et al. "Abstract C114: Androstenedione levels in postmenopausal women with resected early-stage breast cancer are associated with SNPs in CYP11B1 and CYP11B2 identified by a genome-wide association study (GWAS)." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1535-7163.targ-11-c114.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Elrayess, Mohamed, Fatima Al-Khelaifi, Noha Yousri, and Omar Al-Bagha. "Genome-Wide Association study Identifies a Novel Association Between a Cardiovascular Gene Polymorphism and Superior Athletic Performance." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0111.

Full text
Abstract:
Research into the genetic predisposition to superior athletic performance has been a hindered by the underpowered studies and the small effect size of identified genetic variants. The aims of this study were to investigate the association of common single-nucleotide polymorphisms (SNPs) with endurance athlete status in a large cohort of elite European athletes using GWAS approach, followed by replication studies in Russian and Japanese elite athletes and functional validation using metabolomics analysis. Results: The association of 476,728 SNPs of Illumina DrugCore Gene chip and endurance athlete status was investigated in 796 European international-level athletes (645 males, 151 females) by comparing allelic frequencies between athletes specialized in sports with high (n=662) and low/moderate (n=134) aerobic component. Validation of results was performed by comparing the frequencies of the most significant SNPs between 242 and 168 elite Russian high and low/moderate aerobic athletes, respectively, and between 60 elite Japanese endurance athletes and 406 controls. A meta-analysis has identified rs1052373 (GG homozygotes) in Myosin Binding Protein (MYBPC3; implicated in cardiac hypertrophic myopathy) gene to be associated with endurance athlete status (P=1.43E-08, odd ratio 2.2). Homozygotes carriers of rs1052373 G allele in Russian athletes had significantly greater VO2max than carriers of the AA+AG (P = 0.005). Subsequent metabolomics analysis revealed several amino acids and lipids associated with rs1052373 G allele (1.82x10-05) including the testosterone precursor androstenediol (3beta, 17beta) disulfate. Conclusion: This is the first report of genome-wide significant SNP and related metabolites associated with elite athlete status. Further investigations of the functional relevance of the identified SNPs and metabolites in relation to enhanced athletic performance are warranted.
APA, Harvard, Vancouver, ISO, and other styles
5

Palmeira, Evelyn de Souza, Roberto de Azevedo Antunes, Afranio Coelho-Oliveira, Amanda Cristina Barreiros de Souza Lima, and Elaine da Silva Pires Araujo. "Tumor de células da granulosa de ovário associado a manifestações de hiperandrogenismo: relato de caso." In 44° Congresso da SGORJ - XXIII Trocando Ideias. Zeppelini Editorial e Comunicação, 2020. http://dx.doi.org/10.5327/jbg-0368-1416-2020130228.

Full text
Abstract:
Introdução: Os tumores de ovário produtores de hormônios são raros, correspondendo a 5% das neoplasias ovarianas. As manifestações clínicas geradas são resultado do tipo de hormônio produzido, dos níveis séricos e da ação metabólica. Os tumores virilizantes de ovário são uma causa rara de hiperandrogenismo, correspondendo a 0,2% do total de casos. Logo, diante de sinais de hiperandrogenismo, devem ser investigados diagnósticos diferenciais, como a Síndrome do Ovário Policístico (SOP), a hipertecose ovárica, a hiperplasia ou neoplasia das suprarrenais. A produção de androgênios está fundamentalmente associada aos tumores do cordão sexual, mas tumores de células da granulosa também podem produzir. Os sinais de hiperandrogenismo variam de acordo com a idade, manifestando-se na infância como pseudopuberdade precoce heterossexual; no menacme e na menopausa, ocorrem sinais de desfeminização seguidos de virilização. O diagnóstico de um quadro de hiperandrogenismo deve contemplar a dosagem sérica de testosterona total e livre, androstenediona, deidroepiandrosterona e a realização de exames de imagem. Objetivo: Relatar o caso de uma paciente com diagnóstico de neoplasia de células da granulosa em ovário esquerdo, no Hospital Universitário Clementino Fraga Filho (HUCFF), da Universidade Federal do Rio de Janeiro (UFRJ). Caso Clínico: Paciente feminina, 32 anos, portadora de Doença de Cushing diagnosticada em 2011, com história de adrenalectomia bilateral em 2012, em uso regular de prednisona 5 mg/dia e florinef 0,1 mg/dia; com sinais clínicos de hirsutismo, escore 13 da escala de Ferriman-Gallway e história de amenorreia primária, secundária e SOP. Realizou ressonância nuclear magnética da pelve, que evidenciou formação expansiva heterogênea em ovário esquerdo, medindo 5,7×4,8 cm, levantou-se a hipótese de tumor de células Sertoli-Leydig. A avaliação sérica dos marcadores tumorais de neoplasias ovarianas (fração beta da gonadotrofina coriônica humana, antígeno carcinoembriônico CA-125, CA 19-9) apresentaram resultados negativos, o nível de testosterona apresentou elevação. A paciente foi avaliada no Serviço de Ginecologia do HUCFF e realizou cirurgia videolaparoscópica de ooforectomia e salpingectomia esquerda. O histopatológico apresentou resultado de tumor de células da granulosa com estadiamento pT1aNx, confirmado com imuno-histoquímica. Conclusão: Diante de um caso de hiperandrogenismo, devemos proceder com investigação e exclusão de causas tumorais, visto que é uma possibilidade de diagnóstico diferencial. A paciente do caso clínico apresentava causas diferentes para o hiperandrogenismo, como Doença de Cushing e histórico de SOP, contudo a elevação da testosterona sugeriu a possibilidade de neoplasia ovariana. Realizada a investigação, foi comprovada a origem neoplásica ovariana para as manifestações, o que revela a importância da investigação dos diagnósticos diferenciais em casos de hiperandrogenismo.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Androstenedione"

1

Kraus, Cornelia, Kristina A. Pfannkuche, Fritz Trillmich, and Ton G. G. Groothuis. High maternal androstenedione levels during pregnancy in a small precocial mammal with female genital masculinisation. Rostock: Max Planck Institute for Demographic Research, March 2008. http://dx.doi.org/10.4054/mpidr-wp-2008-017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Androstenedione' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography